-DOCSTART- -X- O
During -X- _ O
the -X- _ O
latest -X- _ O
outbreak -X- _ O
of -X- _ O
Ebola -X- _ O
virus -X- _ O
disease -X- _ O
in -X- _ O
West -X- _ O
Africa -X- _ O
, -X- _ O
monoclonal -X- _ O
antibody -X- _ O
therapy -X- _ O
( -X- _ O
e.g. -X- _ O
, -X- _ O
ZMapp -X- _ O
) -X- _ O
was -X- _ O
utilized -X- _ O
to -X- _ O
treat -X- _ O
patients. -X- _ O
However -X- _ O
, -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
antigenic -X- _ O
differences -X- _ O
among -X- _ O
the -X- _ O
five -X- _ O
ebolavirus -X- _ O
species -X- _ O
, -X- _ O
the -X- _ O
current -X- _ O
therapeutic -X- _ O
monoclonal -X- _ O
antibodies -X- _ O
are -X- _ O
only -X- _ O
effective -X- _ O
against -X- _ O
viruses -X- _ O
of -X- _ O
the -X- _ O
species -X- _ O
Zaire -X- _ O
ebolavirus. -X- _ O
Although -X- _ O
this -X- _ O
particular -X- _ O
species -X- _ O
has -X- _ O
indeed -X- _ O
caused -X- _ O
the -X- _ O
majority -X- _ O
of -X- _ O
human -X- _ O
infections -X- _ O
in -X- _ O
Central -X- _ O
and -X- _ O
, -X- _ O
recently -X- _ O
, -X- _ O
West -X- _ O
Africa -X- _ O
, -X- _ O
other -X- _ O
ebolavirus -X- _ O
species -X- _ O
( -X- _ O
e.g. -X- _ O
, -X- _ O
Sudan -X- _ O
ebolavirus -X- _ O
and -X- _ O
Bundibugyo -X- _ O
ebolavirus -X- _ O
) -X- _ O
have -X- _ O
also -X- _ O
repeatedly -X- _ O
caused -X- _ O
outbreaks -X- _ O
in -X- _ O
Central -X- _ O
Africa -X- _ O
and -X- _ O
thus -X- _ O
should -X- _ O
not -X- _ O
be -X- _ O
neglected -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
countermeasures -X- _ O
against -X- _ O
ebolaviruses. -X- _ O
Here -X- _ O
we -X- _ O
report -X- _ O
the -X- _ O
generation -X- _ O
of -X- _ O
an -X- _ O
ebolavirus -X- _ B-Intervention
glycoprotein-specific -X- _ I-Intervention
monoclonal -X- _ I-Intervention
antibody -X- _ I-Intervention
that -X- _ O
effectively -X- _ B-Outcome
inhibits -X- _ I-Outcome
cellular -X- _ I-Outcome
entry -X- _ I-Outcome
of -X- _ I-Outcome
representative -X- _ I-Outcome
isolates -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
known -X- _ I-Outcome
ebolavirus -X- _ I-Outcome
species -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
and -X- _ I-Outcome
show -X- _ I-Outcome
its -X- _ I-Outcome
protective -X- _ I-Outcome
efficacy -X- _ I-Outcome
in -X- _ O
mouse -X- _ B-Patient
models -X- _ I-Patient
of -X- _ I-Patient
ebolavirus -X- _ I-Patient
infections. -X- _ I-Patient
This -X- _ O
novel -X- _ O
neutralizing -X- _ O
monoclonal -X- _ O
antibody -X- _ O
targets -X- _ O
a -X- _ O
highly -X- _ O
conserved -X- _ O
internal -X- _ O
fusion -X- _ O
loop -X- _ O
in -X- _ O
the -X- _ O
glycoprotein -X- _ O
molecule -X- _ O
and -X- _ O
prevents -X- _ O
membrane -X- _ O
fusion -X- _ O
of -X- _ O
the -X- _ O
viral -X- _ O
envelope -X- _ O
with -X- _ O
cellular -X- _ O
membranes. -X- _ O
The -X- _ O
discovery -X- _ O
of -X- _ O
this -X- _ O
highly -X- _ O
cross-neutralizing -X- _ O
antibody -X- _ O
provides -X- _ O
a -X- _ O
promising -X- _ O
option -X- _ O
for -X- _ O
broad-acting -X- _ O
ebolavirus -X- _ O
antibody -X- _ O
therapy -X- _ O
and -X- _ O
will -X- _ O
accelerate -X- _ O
the -X- _ O
design -X- _ O
of -X- _ O
improved -X- _ O
vaccines -X- _ O
that -X- _ O
can -X- _ O
selectively -X- _ O
elicit -X- _ O
cross-neutralizing -X- _ O
antibodies -X- _ O
against -X- _ O
multiple -X- _ O
species -X- _ O
of -X- _ O
ebolaviruses -X- _ O
. -X- _ O

